Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12047) 12047
Publication (1262) 1262
Newsletter (94) 94
Book Review (66) 66
Book Chapter (32) 32
Conference Proceeding (30) 30
Magazine Article (9) 9
Book / eBook (8) 8
Newspaper Article (4) 4
Transcript (2) 2
Web Resource (2) 2
Data Set (1) 1
Dissertation (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11479) 11479
rituximab (9659) 9659
index medicus (6241) 6241
female (6017) 6017
male (5738) 5738
antibodies, monoclonal, murine-derived (5604) 5604
middle aged (4721) 4721
adult (3868) 3868
antibodies, monoclonal - therapeutic use (3708) 3708
aged (3677) 3677
antibodies, monoclonal, murine-derived - therapeutic use (3260) 3260
treatment outcome (3160) 3160
hematology (2764) 2764
oncology (2650) 2650
antineoplastic combined chemotherapy protocols - therapeutic use (2566) 2566
antibodies, monoclonal, murine-derived - administration & dosage (1870) 1870
therapy (1856) 1856
antineoplastic agents - therapeutic use (1788) 1788
antibodies, monoclonal - administration & dosage (1648) 1648
animals (1572) 1572
non-hodgkins-lymphoma (1509) 1509
aged, 80 and over (1469) 1469
immunologic factors - therapeutic use (1463) 1463
cyclophosphamide - administration & dosage (1406) 1406
lymphoma, large b-cell, diffuse - drug therapy (1306) 1306
chemotherapy (1305) 1305
prognosis (1182) 1182
cancer (1145) 1145
antineoplastic combined chemotherapy protocols - administration & dosage (1129) 1129
vincristine - administration & dosage (1124) 1124
retrospective studies (1121) 1121
lymphomas (1103) 1103
mice (1100) 1100
cyclophosphamide - therapeutic use (1090) 1090
doxorubicin - administration & dosage (1063) 1063
antibodies, monoclonal, murine-derived - adverse effects (1031) 1031
immunology (1015) 1015
remission induction (998) 998
care and treatment (979) 979
adolescent (976) 976
prednisone - administration & dosage (976) 976
rheumatology (976) 976
antibodies, monoclonal - adverse effects (972) 972
immunosuppressive agents - therapeutic use (962) 962
transplantation (925) 925
young adult (918) 918
lymphoma (896) 896
prednisone - therapeutic use (890) 890
disease-free survival (850) 850
anti-cd20 monoclonal-antibody (848) 848
cyclophosphamide (842) 842
abridged index medicus (832) 832
recurrence (832) 832
vincristine - therapeutic use (805) 805
follow-up studies (779) 779
doxorubicin - therapeutic use (777) 777
antigens, cd20 - immunology (752) 752
lymphoma, b-cell - drug therapy (745) 745
b-lymphocytes - immunology (735) 735
medicine & public health (731) 731
immunotherapy (713) 713
monoclonal antibodies (703) 703
b-cell lymphoma (668) 668
lymphoma, non-hodgkin - drug therapy (659) 659
combined modality therapy (655) 655
antirheumatic agents - therapeutic use (654) 654
drug therapy, combination (651) 651
antibodies (636) 636
time factors (627) 627
disease (626) 626
drug therapy (626) 626
antineoplastic combined chemotherapy protocols - adverse effects (624) 624
antineoplastic agents - administration & dosage (617) 617
efficacy (594) 594
immunohistochemistry (589) 589
lymphoma, large b-cell, diffuse - pathology (586) 586
trial (583) 583
monoclonal-antibody (581) 581
child (571) 571
chronic lymphocytic-leukemia (567) 567
survival (566) 566
lymphoma, follicular - drug therapy (562) 562
antineoplastic agents (561) 561
arthritis, rheumatoid - drug therapy (561) 561
antibodies, monoclonal - pharmacology (558) 558
risk factors (552) 552
medicine, general & internal (547) 547
expression (538) 538
antineoplastic agents - adverse effects (532) 532
research (532) 532
b-lymphocytes - drug effects (527) 527
analysis (526) 526
drug administration schedule (526) 526
antimitotic agents (519) 519
leukemia, lymphocytic, chronic, b-cell - drug therapy (518) 518
health aspects (498) 498
antibodies, monoclonal - immunology (491) 491
follicular lymphoma (491) 491
hemic and lymphatic diseases (484) 484
antibodies, monoclonal, murine-derived - pharmacology (464) 464
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11037) 11037
Japanese (340) 340
French (178) 178
Chinese (161) 161
German (138) 138
Spanish (114) 114
Russian (51) 51
Hungarian (23) 23
Italian (23) 23
Polish (21) 21
Czech (15) 15
Danish (15) 15
Croatian (11) 11
Dutch (9) 9
Finnish (7) 7
Norwegian (7) 7
Hebrew (6) 6
Portuguese (5) 5
Korean (4) 4
Serbian (3) 3
Romanian (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
by Westin, Jason R, MD and Chu, Fuliang, PhD and Zhang, Min, PhD and Fayad, Luis E, MD and Kwak, Larry W, Prof and Fowler, Nathan, MD and Romaguera, Jorge, Prof and Hagemeister, Fredrick, Prof and Fanale, Michelle, MD and Samaniego, Felipe, MD and Feng, Lei, MS and Baladandayuthapani, Veerabhadran, PhD and Wang, Zhiqiang, PhD and Ma, Wencai, PhD and Gao, Yanli, MS and Wallace, Michael, Prof and Vence, Luis M, PhD and Radvanyi, Laszlo, Prof and Muzzafar, Tariq, MD and Rotem-Yehudar, Rinat, PhD and Davis, R Eric, MD and Neelapu, Sattva S, Dr
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 69 - 77
Summary Background Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | NON-HODGKINS-LYMPHOMA | II TRIAL | MODEL | MONOCLONAL-ANTIBODY THERAPY | T-CELL EXHAUSTION | CANCER | EXPRESSION | PD-1 | TUMOR MICROENVIRONMENT | Recurrence | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - mortality | Rituximab | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Antimitotic agents | Care and treatment | Relapse | Monoclonal antibodies | Lymphomas | Product development | Antineoplastic agents | T cells | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Acceptable changes in quality attributes of glycosylated biopharmaceuticals
by Schiestl, Martin and Stangler, Thomas and Torella, Claudia and Čepeljnik, Tadej and Toll, Hansjörg and Grau, Roger
Nature Biotechnology, ISSN 1087-0156, 04/2011, Volume 29, Issue 4, pp. 310 - 312
MONOCLONAL-ANTIBODIES | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MECHANISMS | Biopharmaceutics - standards | Erythropoietin - analogs & derivatives | European Union | Humans | Chemical Phenomena | Biomedical Technology - standards | Rituximab | Glycosylation | Antibodies, Monoclonal, Murine-Derived - pharmacology | Darbepoetin alfa | Erythropoietin - standards | Biological Products - standards
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
by Cheson, Bruce D and Leonard, John P
The New England Journal of Medicine, ISSN 0028-4793, 08/2008, Volume 359, Issue 6, pp. 613 - 626
Treatment of B-cell non-Hodgkin's lymphoma has become more successful, largely owing to the availability of therapeutic monoclonal antibodies, which may avoid... 
Antigens, CD20 - immunology | Antibodies, Monoclonal, Murine-Derived | Antibodies, Monoclonal - pharmacology | Humans | Rituximab | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Lymphoma, B-Cell - radiotherapy | B-Lymphocytes - immunology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Antigens, Surface | Radioimmunotherapy - adverse effects | Lymphoma, B-Cell - drug therapy | Monoclonal antibodies | Complications and side effects | Dosage and administration | Non-Hodgkin's lymphomas | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
by Goede, Valentin and Fischer, Kirsten and Busch, Raymonde and Engelke, Anja and Eichhorst, Barbara and Wendtner, Clemens M and Chagorova, Tatiana and de la Serna, Javier and Dilhuydy, Marie-Sarah and Illmer, Thomas and Opat, Stephen and Owen, Carolyn J and Samoylova, Olga and Kreuzer, Karl-Anton and Stilgenbauer, Stephan and Döhner, Hartmut and Langerak, Anton W and Ritgen, Matthias and Kneba, Michael and Asikanius, Elina and Humphrey, Kathryn and Wenger, Michael and Hallek, Michael
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 12, pp. 1101 - 1110
Obinutuzumab, a glycoengineered anti-CD20 antibody with increased killing capacity, outperformed rituximab when used in combination with chlorambucil in... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | ILLNESS RATING-SCALE | ANTI-CD20 ANTIBODY | RITUXIMAB | INITIAL THERAPY | CHRONIC LYMPHOCYTIC-LEUKEMIA | GENOMIC ABERRATIONS | PROGRESSION-FREE | 1ST-LINE THERAPY | FLUDARABINE | Antibodies, Monoclonal, Humanized - adverse effects | Antigens, CD20 - immunology | Chlorambucil - administration & dosage | Chlorambucil - adverse effects | Comorbidity | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Rituximab | Remission Induction | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chlorambucil | Chronic lymphocytic leukemia | Usage | Patient outcomes | Dosage and administration | Drug therapy, Combination | Drug therapy | Creatinine | Chronic lymphatic leukemia | Chemotherapy | Leukemia | CD20 antigen | Lymphatic leukemia | Survival | Patients | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
by Herter, Sylvia and Herting, Frank and Mundigl, Olaf and Waldhauer, Inja and Weinzierl, Tina and Fauti, Tanja and Muth, Gunter and Ziegler-Landesberger, Doris and Puijenbroek, Erwin Van and Lang, Sabine and Duong, Minh Ngoc and Reslan, Lina and Gerdes, Christian A and Friess, Thomas and Baer, Ute and Burtscher, Helmut and Weidner, Michael and Dumontet, Charles and Umana, Pablo and Niederfellner, Gerhard and Bacac, Marina and Klein, Christian
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2013, Volume 12, Issue 10, pp. 2031 - 2042
We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with... 
ONCOLOGY | ANTI-CD20 ANTIBODY | B-CELL MALIGNANCIES | HOMOTYPIC ADHESION | CHRONIC LYMPHOCYTIC-LEUKEMIA | NK-CELL | DEATH | MONOCLONAL-ANTIBODIES | HUMAN LYMPHOMA | CYTOTOXICITY | FLUDARABINE | Antibodies, Monoclonal, Humanized - adverse effects | Phagocytosis - drug effects | Apoptosis - drug effects | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Phagocytosis - immunology | Rituximab | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Neoplasms - immunology | Cell Line, Tumor | Mice | Neoplasms - pathology | Cytotoxicity, Immunologic - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
by Furman, Richard R and Sharman, Jeff P and Coutre, Steven E and Cheson, Bruce D and Pagel, John M and Hillmen, Peter and Barrientos, Jacqueline C and Zelenetz, Andrew D and Kipps, Thomas J and Flinn, Ian and Ghia, Paolo and Eradat, Herbert and Ervin, Thomas and Lamanna, Nicole and Coiffier, Bertrand and Pettitt, Andrew R and Ma, Shuo and Stilgenbauer, Stephan and Cramer, Paula and Aiello, Maria and Johnson, Dave M and Miller, Langdon L and Li, Daniel and Jahn, Thomas M and Dansey, Roger D and Hallek, Michael and O'Brien, Susan M
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 11, pp. 997 - 1007
A placebo-controlled study of idelalisib in patients with relapsed chronic lymphocytic leukemia who were receiving rituximab was stopped early because of... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | CAL-101 | PI3K | MUTATION | DISEASE | GENOMIC ABERRATIONS | INHIBITOR | EXPRESSION | Recurrence | Lymph Nodes - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Lymphocytic, Chronic, B-Cell - complications | Aged, 80 and over | Female | Kidney Diseases - complications | Purines - adverse effects | Purines - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Rituximab | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Quinazolinones - therapeutic use | Antibodies, Monoclonal, Murine-Derived - adverse effects | Quinazolinones - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Chronic lymphocytic leukemia | Care and treatment | Medical research | Chronic lymphatic leukemia | Chemotherapy | Renal function | Leukemia | Myelosuppression | Lymphatic leukemia | Kinases | Drug therapy | Survival | 1-Phosphatidylinositol 3-kinase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
by Pescovitz, Mark D and Greenbaum, Carla J and Krause-Steinrauf, Heidi and Becker, Dorothy J and Gitelman, Stephen E and Goland, Robin and Gottlieb, Peter A and Marks, Jennifer B and McGee, Paula F and Moran, Antoinette M and Raskin, Philip and Rodriguez, Henry and Schatz, Desmond A and Wherrett, Diane and Wilson, Darrell M and Lachin, John M and Skyler, Jay S and Type 1 Diabet TrialNet Anti-CD20 and Type 1 Diabetes TrialNet Anti-CD20 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 11/2009, Volume 361, Issue 22, pp. 2143 - 2152
Traditional right ventricular apical pacing can, over time, result in deterioration of left ventricular function. In this comparative-effectiveness trial,... 
RHEUMATOID-ARTHRITIS | DEPENDENT DIABETES-MELLITUS | RESPONSES | MEDICINE, GENERAL & INTERNAL | ANTI-CD20 MONOCLONAL-ANTIBODY | THERAPY | AUTOIMMUNE-DISEASES | IN-VIVO | INSULIN-SECRETION | ANTIGEN-PRESENTING CELLS | CYCLOSPORINE | Glycated Hemoglobin A - analysis | C-Peptide - blood | Area Under Curve | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Young Adult | Adult | Female | Diabetes Mellitus, Type 1 - immunology | Child | Insulin-Secreting Cells - physiology | Antibodies, Monoclonal, Murine-Derived | Double-Blind Method | Antibodies, Monoclonal - pharmacology | B-Lymphocytes - physiology | Rituximab | Diabetes Mellitus, Type 1 - drug therapy | B-Lymphocytes - drug effects | Immunoglobulin M - blood | Insulin-Secreting Cells - drug effects | Diabetes Mellitus, Type 1 - blood | Adolescent | Immunologic Factors - adverse effects | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use | Viral antibodies | Type 1 diabetes | Antibodies | B cells | Diagnosis | Drug therapy | Health aspects | Monoclonal antibodies | Hyperglycemia | Diabetes | Lymphocytes | Cells | Beta
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
by Moessner, Ekkehard and Bruenker, Peter and Moser, Samuel and Puentener, Ursula and Schmidt, Carla and Herter, Sylvia and Grau, Roger and Gerdes, Christian and Nopora, Adam and van Puijenbroek, Erwin and Ferrara, Claudia and Sondermann, Peter and Jaeger, Christiane and Strein, Pamela and Fertig, Georg and Friess, Thomas and Schuell, Christine and Bauer, Sabine and Dal Porto, Joseph and Del Nagro, Christopher and Dabbagh, Karim and Dyer, Martin J. S and Poppema, Sibrand and Klein, Christian and Umana, Pablo
Blood, ISSN 0006-4971, 06/2010, Volume 115, Issue 22, pp. 4393 - 4402
CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin lymphoma as well as autoimmune disorders. B-cell depletion therapy... 
COMPLEMENT | RITUXIMAB | IN-VIVO | LIPID RAFTS | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | MONOCLONAL-ANTIBODY | FOLLICULAR LYMPHOMA | HEMATOLOGY | C-RECEPTOR POLYMORPHISMS | FULLY HUMAN | Lymphoma, Non-Hodgkin - immunology | Neoplasm Transplantation | Humans | Lymphoma, B-Cell - therapy | Macaca fascicularis | Transplantation, Heterologous | Antibodies, Monoclonal, Humanized | Lymphoma, B-Cell - immunology | Protein Engineering | Female | Antibodies, Monoclonal - immunology | Antigens, CD20 - immunology | Antibodies, Monoclonal, Murine-Derived | Antibody-Dependent Cell Cytotoxicity | Antibodies, Monoclonal - pharmacology | Rituximab | Receptors, IgG - immunology | Mice, SCID | Antibodies, Monoclonal - genetics | Animals | B-Lymphocytes - immunology | Lymphoma, Non-Hodgkin - therapy | Cell Line, Tumor | Immunoglobulin Variable Region - genetics | Mice | In Vitro Techniques | Immunity, Cellular | Immunoglobulin Fc Fragments - genetics | Lymphocyte Depletion - methods | Cytotoxicity, Immunologic | Immunobiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
by Hawker, Kathleen and O'Connor, Paul and Freedman, Mark S and Calabresi, Peter A and Antel, Jack and Simon, Jack and Hauser, Stephen and Waubant, Emmanuelle and Vollmer, Timothy and Panitch, Hillel and Zhang, Jiameng and Chin, Peter and Smith, Craig H and OLYMPUS Trial Grp and OLYMPUS trial group
Annals of Neurology, ISSN 0364-5134, 10/2009, Volume 66, Issue 4, pp. 460 - 471
Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting... 
B-CELLS | AUTOANTIBODIES | MRI | NEUROINFLAMMATION | INFLAMMATION | INNATE IMMUNE-SYSTEM | AGED MICE | NEUROSCIENCES | INTERFERON BETA-1A | DAMAGE | EVENT | CLINICAL NEUROLOGY | Antibodies, Monoclonal, Murine-Derived | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Multiple Sclerosis, Chronic Progressive - pathology | Rituximab | Antibodies, Monoclonal - therapeutic use | Male | Multiple Sclerosis, Chronic Progressive - blood | Disease Progression | Young Adult | Multiple Sclerosis, Chronic Progressive - therapy | Antibodies, Monoclonal - administration & dosage | Adolescent | Adult | Female | Aged | Infusions, Intravenous
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Systemic Lupus Erythematosus
by Rahman, Anisur and Isenberg, David A
The New England Journal of Medicine, ISSN 0028-4793, 02/2008, Volume 358, Issue 9, pp. 929 - 939
Systemic lupus erythematosus has many guises, but the unifying feature is the presence of antibodies against double-stranded DNA in almost all patients. This... 
T-Lymphocytes - physiology | Antibodies, Monoclonal, Murine-Derived | Autoantibodies - blood | Humans | B-Lymphocytes - physiology | Rituximab | Antibodies, Monoclonal - therapeutic use | Cytokines - physiology | Autoantibodies - physiology | Autoantigens - immunology | Lupus Erythematosus, Systemic - genetics | Lupus Erythematosus, Systemic - drug therapy | Lupus Erythematosus, Systemic - immunology | Immunologic Factors - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights